Quality of anticoagulation and use of warfarin-interacting medications in long-term care: A chart review

被引：31

作者：

Verhovsek M. ^{[1
]}

Motlagh B. ^{[1
]}

Crowther M.A. ^{[1
]}

Kennedy C. ^{[1
]}

Dolovich L. ^{[1
]}

Campbell G. ^{[2
]}

Wang L. ^{[3
]}

Papaioannou A. ^{[1
]}

机构：

[1] McMaster University, Hamilton, ON

[2] Medical Pharmacies Group Inc., Pickering, ON

[3] St. Joseph's Healthcare, Hamilton, ON

来源：

BMC Geriatrics | / 8卷 / 1期

关键词：

Warfarin; International Normalize Ratio; Warfarin Therapy; Target International Normalize Ratio; International Normalize Ratio Range;

D O I：

10.1186/1471-2318-8-13

中图分类号：

学科分类号：

摘要：

Background. Maintenance of therapeutic International Normalized Ratio (INR) in the community is generally poor. The supervised environment in long-term care facilities may represent a more ideal setting for warfarin therapy since laboratory monitoring, compliance, dose adjustment, and interacting medications can all be monitored and controlled. The objectives of this study were to determine how effectively warfarin was administered to a cohort of residents in long-term care facilities, to identify the proportion of residents prescribed warfarin-interacting drugs and to ascertain factors associated with poor INR control. Methods. A chart review of 105 residents receiving warfarin therapy in five long-term care facilities in Hamilton, Ontario was performed. Data were collected on INR levels, warfarin prescribing and monitoring practices, and use of interacting medications. Results. Over a 12 month period (28,555 resident-days, 78.2 resident years) 3065 INR values were available. Residents were within, below and above the therapeutic range 54%, 35% and 11% of the time, respectively. Seventy-nine percent of residents were prescribed at least one warfarin-interacting medication during the period in review. Residents receiving interacting medications spent less time in the therapeutic range (53.0% vs. 58.2%, OR = 0.93, 95% confidence interval 0.88 to 0.97, P = 0.002). Adequacy of anticoagulation varied significantly between physicians (time in therapeutic range 45.9 to 63.9%). Conclusion. In this group of long-term care residents, warfarin control was suboptimal. Both prescriber and co-prescription of interacting medications were associated with poorer INR control. Future studies should seek strategies to improve prescriber skill and decrease use of interacting medications. © 2008 Verhovsek et al; licensee BioMed Central Ltd.

引用

共 21 条

[11] Samsa G.P., Matchar D.B., Goldstein L.B., Bonito A.J., Lux L.J., Witter D.M., Bian J., Quality of anticoagulation management among patients with atrial fibrillation: Results of a review of medical records from 2 communities, Arch Intern Med, 160, pp. 967-973, (2000)
[12] Holbrook A.M., Pereira J.A., Labiris R., McDonald H., Douketis J.D., Crowther M., Wells P.S., Systematic overview of warfarin and its drug and food interactions, Arch Intern Med, 165, pp. 1095-1106, (2005)
[13] Rosendaal F.R., Cannegieter S.C., Van Der Meer F.J., Briet E., A method to determine the optimal intensity of oral anticoagulant therapy, Thromb Haemost, 69, pp. 236-239, (1993)
[14] Raebel M.A., Witt D.M., Carroll N.M., Magid D.J., Warfarin monitoring in ambulatory older individuals receiving antimicrobial therapy, Pharmacotherapy, 25, pp. 1055-1061, (2005)
[15] Gurwitz J.H., Monette J., Rochon P.A., Eckler M.A., Avorn J., Atrial fibrillation and stroke prevention with warfarin in the long-term care setting, Arch Intern Med, 157, pp. 978-984, (1997)
[16] Gurwitz J.H., Field T.S., Radford M.J., Harrold L.R., Becker R., Reed G., Debellis K., Moldoff J., Verzier N., The safety of warfarin therapy in the nursing home setting, Am J Med, 120, pp. 539-544, (2007)
[17] McCormick D., Gurwitz J.H., Goldberg R.J., Becker R., Tate J.P., Elwell A., Radford M.J., Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting, Arch Intern Med, 161, pp. 2458-2463, (2001)
[18] Samsa G.P., Matchar D.B., Relationship between test frequency and outcomes of anticoagulation: A literature review and commentary with implications for the design of randomized trials of patient self-management, J Thromb Thrombolysis, 9, pp. 283-292, (2000)
[19] Horstkotte D., Piper C., Wiemer M., Optimal Frequency of Patient Monitoring and Intensity of Oral Anticoagulation Therapy in Valvular Heart Disease, J Thromb Thrombolysis, 51, pp. 19-24, (1998)
[20] Feldstein A.C., Smith D.H., Perrin N., Yang X., Simon S.R., Krall M., Sittig D.F., Ditmer D., Platt R., Soumerai S.B., Reducing warfarin medication interactions: An interrupted time series evaluation, Arch Intern Med, 166, pp. 1009-1015, (2006)

← 1 2 3 →